transcranial magnetic stimulation (TMS, rTMS)
Jump to navigation
Jump to search
Indications
- depression[1] - FDA-approved device for persons 15-12 years[6]*
- migraine[2]
- obsessive compulsive disorder[2]
- diagnosis of dementia
- reliably & selectively distinguishes
* repetitive transcranial magnetic stimulation (rTMS) can be effective in depressed patients who don't respond to initial antidepressant drug therapy[7][8]
Procedure
- application of magnetic fields strong enough to alter cerebral cortex neuron firing patterns
- applied over left dorsal frontal cortex
Notes
- effective in controlled trials.
More general terms
References
- ↑ 1.0 1.1 George MS et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Arch Gen Psychiatry 2010 May; 67:507. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20439832
- ↑ 2.0 2.1 2.2 FDA News Release. August 17, 2018 FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm617244.htm
- ↑ Brooks M FDA Clears 3-Minute Brain Stimulation Protocol for Depression. Medscape - Aug 22, 2018. https://www.medscape.com/viewarticle/901052
- ↑ Hlavinka E, MedPage Today. Dec 30, 2018 Magnetic Brain Stimulation: 'Huge Amount of Promise' - TMS could still shift the psychiatric treatment paradigm, despite failure in VA trial. https://www.medpagetoday.com/psychiatry/depression/77180
Yesavage JA, Fairchild JK, Mi Z et al Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans. A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(9):884-893 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29955803 https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2686050 - ↑ 5.0 5.1 Benussi A, Grassi M, Paslluzzi F et al. Classification accuracy of transcranial magnetic stimulation for the diagnosis of neurodegenerative dementias. Ann Neurol 2020 Jan 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31925823 https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.25677
- ↑ 6.0 6.1 Bagha S FDA grants clearance to TMS device for MDD in young people. Healio. March 28, 2024 https://www.healio.com/news/psychiatry/20240328/fda-grants-clearance-to-tms-device-for-mdd-in-young-people
- ↑ 7.0 7.1 Dalhuisen I, van Oostrom I, Spijker J et al rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches. Am J Psychiatry. 2024 Sep 1;181(9):806-814. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39108161 Clinical Trial.
- ↑ 8.0 8.1 Papakostas GI, Trivedi MH, Shelton RC et al Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug;29(8):2287-2295. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38454079 PMCID: PMC11412904 Free PMC article. Clinical Trial.